myome®

Proactive Health
INTEGRATED RISK™
CORONARY ARTERY DISEASE

A Personalized Risk Score for Coronary Artery Disease

MyOme's Integrated Polygenic Risk Score™ (iPRS™) Coronary Artery Disease (CAD) test combines whole-genome with clinical risk asessment, delivering a more accurate risk prediction to guide healthcare decisions.

Better Risk Prediction can Tailor Management to Improve Health Outcomes

Comprehensive Analysis

Approximately

50%

of CAD risk is due to heritable factors, many of which can be detected as genetic markers by the iPRS test.[1]

Reliable Risk Stratification

Nearly

10%

of patients with uncertain* 10-year risk of CAD (as determined by traditional methods) were reclassified as high-risk by iPRS.[2]

Hidden Risk Detection

Cases reclassified by iPRS had

3X

higher 10-year risk of CAD incidence, underscoring the value of accurate risk stratification.[2]

iPRS for Coronary Artery Disease

Patients can receive an iPRS result if they:

- Are aged 40-79
- Do not have a personal history of CAD
- Have all clinical measurements required to calculate risk

PRS

Includes >6M genetic risk factors

+

ASCVD Pooled Cohort Equations (PCE) Model[3]**

Includes clinical inputs from health history

*Uncertain risk is defined as having borderline or intermediate risk scores
**Atheroschlerotic Cardiovascular Disease

myome®

Proactive Health
INTEGRATED RISK™
CORONARY ARTERY DISEASE

Key Features

Multi-Ancestry Applicability

Data from >150K patients in four large international cohorts was used to validate iPRS, enabling cross-ancestry risk prediction[2]

Actionable Recommendations

Results include recommendations for a heart-healthy lifestyle and may recommend that providers start patients on medication

Genetic Counseling

Optional support from a trained genetic counselor is available to help ensure comprehensive risk assessment and management

Important Considerations: The iPRS CAD test is intended as a risk assessment tool, NOT a diagnostic. Some people with a high risk score will not develop CAD and some with a low risk score will develop CAD.

A Simple, Seamless Process

Ordering	Sample Collection	Sample Analysis	Receiving Results
Submit a request via MyOme's secure portal	Use instructions provided in blood, saliva, or buccal swab collection kits	Return sample to MyOme for sequencing and data analysis	Reports with risk assessment results and relevant actionable insights are delivered through a secure portal

Support at Every Step

We are committed to helping providers communicate complex topics by providing videos, materials, and other resources to support patient education.

Get started with MyOme today.
Contact support@myome.com to set up an account.

This test was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.

1. McPherson R and Tybjaerg-Hansen A. Genetics of CAD. Circulation Research. 19 Feb 2016; 118 (4). doi: 10.1161/CIRCRESAHA.115.306566.**2**. Ratman D, Tshiaba P, Levin M, et al. PRS Improves 10-year Risk Prediction of Coronary Artery Disease in Individuals at Uncertain Clinical Risk. JAMA (in revision). 2024. **3.** Medina-Inojosa J, Somers V, Garcia M, et al. Performance of the ACC/AHA Pooled Cohort Equations in Clinical Practice. J Am Coll Cardiol. 2023 Oct 10; 82(15):1499-1508. doi: 10.1016/j.jacc.2023.07.018.

 | 535 Middlefield Rd, Suite 170, Menlo Park, CA 94025 | www.myome.com | M-069_C v1 02/25